Cumming D V, Heads R J, Coffin R S, Yellon D M, Latchman D S
Department of Molecular Pathology, University College London Medical School, United Kingdom.
Basic Res Cardiol. 1996 Sep-Oct;91(5):367-73. doi: 10.1007/BF00788716.
Pre-treatment with the immunosuppressant FK506 is shown to protect primary cardiocytes against a subsequent severe thermal or ischaemic stress. This effect is not observed with the related compounds cyclosporin A or rapamycin. It does not involve induction of the FK506 binding, heat inducible protein hsp56 or of the other heat shock proteins. In addition over-expression of hsp56 does not protect cardiac cells from severe stress in contrast to our previous results with hsp70 and hsp90. These results suggest the FK506 is acting via a novel mechanism to protect cardiac cells against cellular ischaemia which may not be related to its immunosuppressant action.
研究表明,使用免疫抑制剂FK506进行预处理可保护原代心肌细胞免受随后严重的热应激或缺血应激。相关化合物环孢素A或雷帕霉素未观察到这种效果。它不涉及诱导FK506结合、热诱导蛋白hsp56或其他热休克蛋白。此外,与我们之前关于hsp70和hsp90的结果相反,hsp56的过表达并不能保护心脏细胞免受严重应激。这些结果表明,FK506通过一种新机制发挥作用,保护心脏细胞免受细胞缺血的影响,这可能与其免疫抑制作用无关。